We then evaluated the ability of clinical PD-L1/PD-1 ICBs (at a concentration of 10 μg/mL) to block PD-L1/PD-1 interactions when the cancer cells were fixed, therefore not giving rise to sPD-L1 presence in the cell media. This evidence concerns the gene SPDL1 and cancer.